227 related articles for article (PubMed ID: 9733874)
21. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen.
Landais E; Saulquin X; Bonneville M; Houssaint E
J Immunol; 2005 Dec; 175(12):7939-46. PubMed ID: 16339529
[TBL] [Abstract][Full Text] [Related]
22. Presentation of soluble antigen to human T cells by products of multiple HLA-linked loci: analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant Epstein-Barr virus-transformed lymphoblastoid cell lines.
Chen BP; DeMars R; Sondel PM
Hum Immunol; 1987 Jan; 18(1):75-91. PubMed ID: 3542914
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
[TBL] [Abstract][Full Text] [Related]
24. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
25. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors.
Wilson AD; Hopkins JC; Morgan AJ
Clin Exp Immunol; 2001 Oct; 126(1):101-10. PubMed ID: 11678905
[TBL] [Abstract][Full Text] [Related]
26. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
27. Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response.
Sugano M; Conway TF; Kelleher RJ; Sugiyama Y; Chen FA; Bankert RB; Bernstein SH
J Exp Clin Cancer Res; 2001 Jun; 20(2):175-82. PubMed ID: 11484971
[TBL] [Abstract][Full Text] [Related]
28. Requirement of Ia-positive accessory cells in the MLR response against class II antigen on human B cell tumor line.
Yamamoto M; Yano A
J Immunol; 1985 Dec; 135(6):3887-96. PubMed ID: 2999233
[TBL] [Abstract][Full Text] [Related]
29. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
30. STAT1 contributes to the maintenance of the latency III viral programme observed in Epstein-Barr virus-transformed B cells and their recognition by CD8+ T cells.
McLaren JE; Zuo J; Grimstead J; Poghosyan Z; Bell AI; Rowe M; Brennan P
J Gen Virol; 2009 Sep; 90(Pt 9):2239-50. PubMed ID: 19439556
[TBL] [Abstract][Full Text] [Related]
31. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
32. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus-transformed B cell lines present M. leprae antigens to T cells.
Elferink BG; Ottenhoff TH; de Vries RR
Scand J Immunol; 1985 Nov; 22(5):585-9. PubMed ID: 3001928
[TBL] [Abstract][Full Text] [Related]
34. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells.
Taylor GS; Long HM; Haigh TA; Larsen M; Brooks J; Rickinson AB
J Immunol; 2006 Sep; 177(6):3746-56. PubMed ID: 16951335
[TBL] [Abstract][Full Text] [Related]
35. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.
Torsteinsdottir S; Masucci MG; Ehlin-Henriksson B; Brautbar C; Ben Bassat H; Klein G; Klein E
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5620-4. PubMed ID: 3016710
[TBL] [Abstract][Full Text] [Related]
36. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
37. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205.
Leung CS; Maurer MA; Meixlsperger S; Lippmann A; Cheong C; Zuo J; Haigh TA; Taylor GS; Münz C
Blood; 2013 Feb; 121(9):1584-94. PubMed ID: 23297134
[TBL] [Abstract][Full Text] [Related]
38. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
Ulaeto D; Wallace L; Morgan A; Morein B; Rickinson AB
Eur J Immunol; 1988 Nov; 18(11):1689-97. PubMed ID: 2904885
[TBL] [Abstract][Full Text] [Related]
39. A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells.
Behar SM; Porcelli SA; Beckman EM; Brenner MB
J Exp Med; 1995 Dec; 182(6):2007-18. PubMed ID: 7500046
[TBL] [Abstract][Full Text] [Related]
40. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design.
Thomson SA; Burrows SR; Misko IS; Moss DJ; Coupar BE; Khanna R
J Virol; 1998 Mar; 72(3):2246-52. PubMed ID: 9499082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
